Discontinuation or Continuation of IO Therapy – IO/IO vs. IO/TKI Regimens
Dr. Campbell evaluates the efficacy and safety results from the 55-month analysis of the CheckMate-9ER trial, and explores the considerations for discontinuing or continuing immunotherapy (IO) in IO/IO versus IO/TKI combination regimens.
- Dr Campbell: Please briefly review key efficacy and safety data from the CheckMate-9ER trial 55 month analysis (Bourlon MT, et al. 2024 ASCO Annual Meeting. Abstract 362).
- What are the clinical implications of these data for treatment-naïve patients with advanced RCC?
- In responders, how important is the durability of the response (OS and PFS) for both the intermediate/poor and favorable-risk groups?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Promising Results from Phase 1/2 Trial of NKT2152 for Advanced Kidney Cancer
September 20th 2024NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.
Read More
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More
